Two year Phase III study shows Novartis oral MS therapy FTY720 (fingolimod) significantly reduces re
For UK consumer health journalists ¢ Fingolimod significantly reduced annualised relapse rates by 54-60% vs placebo and disability progression by 30-32% in two-year FREEDOMS study1 ¢ Results bui... Latest articles from Network Norwich and Norfolk Join in for a morning of walking meditation, with facilitated personal and shared reflection, focused on Norwich Cathedrals Labyrinth and based in the new Hostry on Saturday 27 March. By ..
From: Network Norwich 5 hours ago

